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pNTRODUCTION
Reminiscent of the organs from which they arise,
ost cancers are composed of a heterogenous popu-
ation of cells with marked differences in their prolif-
rative potential, as well as the ability to reconstitute
he tumor upon transplantation. Cancer stem cells are
minor population of tumor cells that possess the
tem cell property of self-renewal. In addition, dys-
egulation of stem cell self-renewal is a likely require-
ent for the development of cancer. This new model
or cancer will have signiﬁcant ramiﬁcations for the
ay we study and treat cancer. In addition, through
argeting the cancer stem cell and its dysregulated
elf-renewal, our therapies for treating cancer are
ikely to improve.
Recent evidence has demonstrated that in solid
umors, only a minority of cancer cells have the ca-
acity to proliferate extensively and form new tumors
Figure 1). These tumorigenic cells, or tumor-initiat-
ng cells (TICs), have been identiﬁed and enriched on
he basis of their expression of cell-surface markers.
pon transplantation, TICs give rise to tumors com-
osed of both new TICs and heterogeneous popula-
ions of nontumorigenic cells, reminiscent of the de-
elopmental hierarchy in the tissues from which the
umors arise. Most adult tissues are maintained over
he lifetime of the host by normal stem cells that
ndergo expansion and differentiation to yield the
unctional elements of the organ. Through the tightly
egulated process of self-renewal, stem cells are able to
unction over the life span of the host. The genetic
onstraints on self-renewal restrict the expansion of
tem cells in healthy tissues. Breakdown in the regu-
ation of self-renewal is likely a key event in the de-
elopment of cancer, as demonstrated by the fact that
everal pathways implicated in carcinogenesis also play b
4key role in normal stem cell self-renewal decisions.
hus, malignant tumors can viewed as abnormal or-
ans in which a minority population of tumorigenic
ancer cells have escaped the normal constraints on
elf-renewal, giving rise to abnormally differentiated
ancer cells that have lost the ability to form tumors.
his new model for cancer has important implications
or the study and treatment of malignancies.
HAT IS A STEM CELL?
Normal tissue stem cells are deﬁned by 3 common
roperties: (1) the presence of an extensive capacity
or self-renewal, which allows maintenance of the un-
ifferentiated stem cell pool over the lifetime of the
ost; (2) strict regulation of stem cell number; and (3)
he ability to undergo a broad range of differentiation
vents to clonally reconstitute all of the functional
lements in the tissue. It is important to note that the
tem cells in each tissue differ with respect to their
ntrinsic ability both to self-renew and to differentiate
nto particular mature cell types.
ELF-RENEWAL AND CANCER
Self-renewal is a cell division in which 1 or both of
he resulting daughter cells remain undifferentiated
nd retain the ability to give rise to another stem cell
ith the same capacity to proliferate as the parental
ell. Proliferation, unlike self-renewal, does not re-
uire either daughter cell to be a stem cell or to retain
he ability to give rise to a differentiated progeny. The
ommitted progenitor cell is destined to stop prolif-
rating, because with each cell division, its potential to
roliferate decreases. In normal tissues, such as the
lood, both stem cells and committed progenitor cells
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Bave an extensive capacity to proliferate. Whereas
ommitted progenitor populations can maintain he-
atopoiesis for up to 6 to 8 weeks, a single hemato-
oietic stem cell can restore the blood system for the
ife of the animal. This tremendous potential is a
irect result of its capacity to self-renew.
Most tumors develop over a period of months to
ears and, as do normal tissues, consist of heteroge-
eous populations of cells. In previous models of can-
er, the unregulated growth of tumors was attributed
o the serial acquisition of genetic events, which re-
ulted in turning on genes promoting proliferation,
ilencing genes involved in inhibiting proliferation,
nd circumventing genes involved in programmed cell
eath. In the stem cell model for cancer, another key
vent in tumorigenesis is the disruption of genes in-
olved in the regulation of stem cell self-renewal.
hus, some of the cancer cells within a tumor share
ith normal stem cells the ability to replicate without
osing the capacity to proliferate.
It is not surprising, then, that a number of genes
nitially identiﬁed for their role in carcinogenesis have
een implicated in normal stem cell self-renewal deci-
ions. Genes that have been demonstrated to be involved
n regulation of self-renewal in normal stem cells include
he Bmi-1, Notch, Wnt, and Shh pathways.
The Polycomb and trithorax groups are transcrip-
ional repressors and activators that are part of mul-
imeric complexes that interact with DNA and lead to
ither a repressed or an activated state of gene expres-
ion, respectively. Bmi-1, a member of the Polycomb
igure 1. Isolation of cancer stem cells. Human tumor cells are
issociated and, on the basis of marker expression, are isolated by
ow cytometry for injection into immunodeﬁcient mice. Different
opulations of tumor cells differ with respect to their ability to form
umors, demonstrating a cancer stem cell population within the
umor.roup, targets the INK4a locus, and overexpression of t
B & M Tmi-1 results in downregulation of both p16 and
19Arf. Postnatal mice deﬁcient in the expression of
mi-1 display failure of hematopoiesis, and fetal liver
nd bone marrow stem cells from Bmi/ mice are
ble to contribute to recipient hematopoiesis only
ransiently; this indicates a primary defect in adult
ematopoietic stem cell self-renewal. Bmi-1 also plays
key role in malignant hematopoiesis: HOXA9/
EIS1-induced murine leukemia is dependent on the
xpression of Bmi-1.
The importance of epigenetic events in normal
nd malignant tissues is likely to remain a key focus of
esearch. Preliminary studies have examined the abil-
ty to reverse these epigenetic changes through the
ransfer of nuclei from cells in a differentiated tissue
nto enucleated oocytes. Nuclei obtained from medul-
oblastoma tumor cells arising in Ptc1 heterozygous
ice were transferred into enucleated oocytes. Blas-
ocysts derived from medulloblastoma were morpho-
ogically indistinguishable from those derived from
ontrol spleen cell nuclei without evidence of uncon-
rolled proliferation. This study suggests that epige-
etic reprogramming was responsible for the loss of
he tumor cells’ capacity to form tumors.
MPLICATIONS OF THE STEM CELL MODEL FOR
ANCER
There are major implications for the way we
tudy, diagnose, and treat cancer if the same popula-
Therapeutic Implications of Cancer Stem Cells
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The self-renewing
cancer stem cell
regenerates the tumor
The tumor 
inititially
shrinks-
but
The tumor is eliminated
igure 2. Improved cancer treatment based on targeting tumor-
nitiating cells (TICs). Most traditional treatments are developed
nd assayed on the basis of their ability to kill most of a tumor cell
opulation—eg, “log-kill” assays. However, these treatments can
asily miss the TICs, particularly because they have evolved to
verexpress drug efﬂux pumps. This model explains why standard
hemotherapy often results in remissions, but not cures. Treat-
ents targeted speciﬁcally at TICs, in contrast, would be more
ffective at truly curing the tumor, because more differentiated
umor cells would eventually become quiescent, or apoptose.
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1ions of cancer cells are tumorigenic in humans and
he xenograft model. If only a rare subset of tumor
tem cells drives tumor formation, then the goal of
herapy should be to identify this population and then
evelop therapies that target it. Current therapeutic
trategies fail to account for potential differences in
rug sensitivity or target expression between the TICs
nd the more frequent nontumorigenic cells. A differ-
ntial sensitivity to treatment between the tumori-
enic and nontumorigenic populations may account
or the difﬁculty in developing therapies that are con-
istently able to eradicate solid tumors other than
esticular cancer (Figure 2).
This new model for cancer will also likely affect
ur understanding of the mechanisms of drug resis-
ance. A wide variety of transporters, including mem-
ers of the ABC transporter family, have been dem-
nstrated on normal stem cells, and several of these
ransporters have well-established roles in drug efﬂux.
he ability of leukemic progenitors to efﬂux mitox-
ntrone and daunorubicin, 2 agents commonly used in w
6reatment of acute myeloid leukemia, has also been
hown. Thus, our understanding of drug sensitivity
nd the development of drug resistance by tumors
ight be signiﬁcantly affected by the fact that only a
are subset of tumor stem cells drives tumorigenesis.
In addition to its effect on our understanding of
he efﬁcacy of our current therapies, the stem cell
odel for cancer is likely to affect the identiﬁcation of
uture therapeutic targets. The expression patterns of
ormal stem cells and their more differentiated prog-
ny can differ signiﬁcantly. DNA and tissue microar-
ays of tumors to date have failed to account for
ellular heterogeneity and differences in the prolifer-
tive potential of these different populations. By di-
ecting expression analyses to enriched populations of
umorigenic cancer cells, the identiﬁcation of novel
iagnostic markers and novel therapeutic targets
hould be more effective. In addition, it is becoming
pparent that treatments that directly target the path-
ays involved in malignant stem cell self-renewal
ould have a signiﬁcantly greater chance of success.
